Updated pan-tumor guidelines for neoadjuvant scoring of pathologic response: a joint SITC and INMC effort.
A live tumor fragment platform to assess immunotherapy response in core needle biopsies while addressing challenges of tumor heterogeneity.
Pan-tumor harmonization of pathologic response assessment for standardized data collection in neoadjuvant trials (PATHdata): results of a Society for Immunotherapy of Cancer multi-institutional reproducibility study.
Upping the ‘plex’: Whole-slide, automated fourteen-color multiplex immunofluorescence staining of the tumor microenvironment in paraffin embedded tissue
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer
Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB–D melanoma: a phase 1/2 trial
Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols
Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB-D melanoma: a phase 1/2 trial.
Society for Immunotherapy of Cancer: updates and best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) image analysis and data sharing
Divergent Clinical and Immunologic Outcomes Based on STK11 Co-mutation Status in Resectable KRAS-Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade.
Rationale and feasibility of a rapid integral biomarker program that informs immune-oncology clinical trials: the ADVISE trial.
Concordance of Whole-Slide Imaging and Conventional Light Microscopy for Assessment of Pathologic Response Following Neoadjuvant Therapy for Lung Cancer
Perioperative nivolumab or nivolumab plus ipilimumab in resectable diffuse pleural mesothelioma: a phase 2 trial and ctDNA analyses.
AstroID resource: a scalable, relational database structure for longitudinal biomarker discovery.
Society for Immunotherapy of Cancer: Standards for Reporting of Multiplex Immunohistochemistry/Immunofluorescence Assays (STORMI).
Figure S1 from Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer
Figure S2 from Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer
Figure S1 from Divergent Clinical and Immunologic Outcomes Based on <i>STK11</i> Co-mutation Status in Resectable <i>KRAS-</i>Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade
Figure S6 from Divergent Clinical and Immunologic Outcomes Based on <i>STK11</i> Co-mutation Status in Resectable <i>KRAS-</i>Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade
Figure S4 from Divergent Clinical and Immunologic Outcomes Based on <i>STK11</i> Co-mutation Status in Resectable <i>KRAS-</i>Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade
Figure S5 from Divergent Clinical and Immunologic Outcomes Based on <i>STK11</i> Co-mutation Status in Resectable <i>KRAS-</i>Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade
Figure S3 from Divergent Clinical and Immunologic Outcomes Based on <i>STK11</i> Co-mutation Status in Resectable <i>KRAS-</i>Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade
Supplementary Tables 1 from Divergent Clinical and Immunologic Outcomes Based on <i>STK11</i> Co-mutation Status in Resectable <i>KRAS-</i>Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade
Figure S2 from Divergent Clinical and Immunologic Outcomes Based on <i>STK11</i> Co-mutation Status in Resectable <i>KRAS-</i>Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade
Data from Divergent Clinical and Immunologic Outcomes Based on <i>STK11</i> Co-mutation Status in Resectable <i>KRAS-</i>Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade
Perioperative Nivolumab in Resectable Lung Cancer
Association between pathologic response and survival after neoadjuvant therapy in lung cancer.
Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC
Neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with resectable NSCLC: 4-year update from CheckMate 816.
Nivolumab + Tacrolimus + Prednisone ± Ipilimumab for Kidney Transplant Recipients With Advanced Cutaneous Cancers.